drugset / Trial / NCT05489289
A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The efficacy and safety of AK104 as adjuvant therapy in hepatocellular carcinoma of high recurrence risk after curative resection.
Timeline
- Start
- 2023-01-05
- Primary completion
- 2026-01-28
- Completion
- 2027-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cadonilimab | Monoclonal antibody | — | Intravenous |